Saltar para:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Início > Publicações > Visualização > The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

Título
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
Tipo
Artigo em Revista Científica Internacional
Ano
2019
Autores
Reis Mendes, A
(Autor)
Outra
A pessoa não pertence à instituição. A pessoa não pertence à instituição. A pessoa não pertence à instituição. Sem AUTHENTICUS Sem ORCID
Felix Carvalho
(Autor)
FFUP
Ver página pessoal Sem permissões para visualizar e-mail institucional Pesquisar Publicações do Participante Ver página do Authenticus Sem ORCID
Fernando Remiao
(Autor)
FFUP
Emilia Sousa
(Autor)
FFUP
Ver página pessoal Sem permissões para visualizar e-mail institucional Pesquisar Publicações do Participante Ver página do Authenticus Sem ORCID
Maria de Lourdes Bastos
(Autor)
FFUP
Costa, VM
(Autor)
Outra
A pessoa não pertence à instituição. A pessoa não pertence à instituição. A pessoa não pertence à instituição. Sem AUTHENTICUS Sem ORCID
Revista
Título: BiomoleculesImportada do Authenticus Pesquisar Publicações da Revista
Vol. 9 9
Página Final: 98
ISSN: 2218-273X
Editora: MDPI
Outras Informações
ID Authenticus: P-00Q-AXH
Abstract (EN): In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms are still unclear. In the present study, the role of the main metabolites regarding FAC-induced cardiotoxicity was assessed at clinical relevant concentrations. Seven-day differentiated H9c2 cells were exposed for 48 h to the main metabolites of FAC, namely the metabolite of 5-FU, ¿-fluoro-ß-alanine (FBAL, 50 or 100 ¿M), of DOX, doxorubicinol (DOXOL, 0.2 or 1 ¿M), and of CYA, acrolein (ACRO, 1 or 10 ¿M), as well as to their combination. The parent drugs (5-FU 50 ¿M, DOX 1 ¿M, and CYA 50 ¿M) were also tested isolated or in combination with the metabolites. Putative cytotoxicity was evaluated through phase contrast microscopy, Hoechst staining, membrane mitochondrial potential, and by two cytotoxicity assays: the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the neutral red (NR) lysosomal incorporation. The metabolite DOXOL was more toxic than FBAL and ACRO in the MTT and NR assays. When in combination, neither FBAL nor ACRO increased DOXOL-induced cytotoxicity. No nuclear condensation was observed for any of the tested combinations; however, a significant mitochondrial potential depolarization after FBAL 100 ¿M + DOXOL 1 ¿M + ACRO 10 ¿M or FBAL 100 ¿M + DOXOL 1 ¿M exposure was seen at 48 h. When tested alone DOX 1 ¿M was more cytotoxic than all the parent drugs and metabolites in both the cytotoxicity assays performed. These results demonstrated that DOXOL was the most toxic of all the metabolites tested; nonetheless, the metabolites do not seem to be the major contributors to FAC-induced cardiotoxicity in this cardiac model.
Idioma: Inglês
Tipo (Avaliação Docente): Científica
Nº de páginas: 20
Documentos
Não foi encontrado nenhum documento associado à publicação.
Publicações Relacionadas

Dos mesmos autores

Unveiling the cardiotoxicity of anticancer drugs: A comparative in vitro study between mitoxantrone and its naphthoquinoxaline metabolite (2015)
Outras Publicações
Reis Mendes, A; Gomes, AS; Carvalho, RA; Fernando Remiao; Felix Carvalho; Pinto, M; Maria de Lourdes Bastos; Emilia Sousa; Costa, VM
Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy (2017)
Artigo em Revista Científica Internacional
Reis Mendes, A; Gomes, AS; Carvalho, RA; Felix Carvalho; Fernando Remiao; Pinto, M; Maria de Lourdes Bastos; Emilia Sousa; Costa, VM
Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells (2022)
Artigo em Revista Científica Internacional
Reis Mendes, A; Felix Carvalho; Fernando Remiao; Emilia Sousa; Maria de Lourdes Bastos; Costa, VM

Da mesma revista

The Impact of Flavonoid-Loaded Nanoparticles in the UV Protection and Safety Profile of Topical Sunscreens (2023)
Outra Publicação em Revista Científica Internacional
Fonseca, M; Rehman, M; soares, r; Fonte, P
Stalling the Course of Neurodegenerative Diseases: Could Cyanobacteria Constitute a New Approach toward Therapy? (2023)
Outra Publicação em Revista Científica Internacional
Ramos, V; Reis, M; Ferreira, L; Silva, AM; Ferraz, R; Vieira, M; Vitor Vasconcelos; Martins, R
Saquinavir: From HIV to COVID-19 and Cancer Treatment (2022)
Outra Publicação em Revista Científica Internacional
Pereira, M; Nuno Vale
Natural Sympathomimetic Drugs: From Pharmacology to Toxicology (2022)
Outra Publicação em Revista Científica Internacional
Costa, VM; Grando, LGR; Milandri, E; Nardi, J; Teixeira, P; Mladenka, P; Fernando Remiao
Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems (2020)
Outra Publicação em Revista Científica Internacional
Baldim, I; Oliveira, WP; Kadian, V; Rao, R; Yadav, N; Mahant, S; Lucarini, M; Durazzo, A; Da Ana, R; Capasso, R; Souto, SB; Santini, A; Souto, EB

Ver todas (51)

Recomendar Página Voltar ao Topo